 Compugen Ltd NASDAQ: CGEN expands its clinical collaboration agreement with Bristol-Myers Squibb Co NYSE: BMY, wherein Bristol Myers will supply Opdivo nivolumab for Compugens Phase 1b cohort expansion study evaluating COM701, anti-PVRIG antibody. The study will assess COM701 combined with Opdivo in selected cancer indications, expected to start in the second quarter of 2021. 